Impact of Dimethylfumarate on Sleep in Multiple Sclerosis Patients: An Actigraphic Study.
Sleep
actigraphy
dimethylfumarate
disease-modifying treatment
multiple sclerosis
sleep disorders
Journal
CNS & neurological disorders drug targets
ISSN: 1996-3181
Titre abrégé: CNS Neurol Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269155
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
10
2021
revised:
22
02
2022
accepted:
03
03
2022
medline:
17
5
2023
pubmed:
17
5
2022
entrez:
16
5
2022
Statut:
ppublish
Résumé
Sleep disorders in multiple sclerosis (MS) patients are common. Dimethylfumarate is an oral disease-modifying drug (DMT), whose impact on sleep is unknown. The aim of this study was to characterize actigraphic patterns in MS patients treated with dimethylfumarate. Twenty relapsing-remitting MS patients with low to a mild disability, aged 20-50y, treated with dimethylfumarate for more than 6 months, were enrolled. All subjects had no history of sleep disorders. Actigraphy was used to study sleep patterns during a seven-day period. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Twenty healthy subjects served as controls. Our results showed statistically significant differences between some actigraphic patterns in MS patients treated with dimethylfumarate and healthy subjects, but the values for patients were still within normal limits. PSQI score was higher in MS patients compared to controls. Our findings suggest that dimethylfumarate, an oral DMT with a favourable benefit-risk profile, does not strongly alter sleep patterns in MS patients with low to mild disability and with no history of sleep disorders. Actigraphy is a simple diagnostic tool, able to support an objective measure of sleep parameters. The simplicity of application may allow considering its use for a screening of sleep disorders in MS patients.
Sections du résumé
BACKGROUND
Sleep disorders in multiple sclerosis (MS) patients are common. Dimethylfumarate is an oral disease-modifying drug (DMT), whose impact on sleep is unknown.
OBJECTIVE
The aim of this study was to characterize actigraphic patterns in MS patients treated with dimethylfumarate.
METHODS
Twenty relapsing-remitting MS patients with low to a mild disability, aged 20-50y, treated with dimethylfumarate for more than 6 months, were enrolled. All subjects had no history of sleep disorders. Actigraphy was used to study sleep patterns during a seven-day period. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Twenty healthy subjects served as controls.
RESULTS
Our results showed statistically significant differences between some actigraphic patterns in MS patients treated with dimethylfumarate and healthy subjects, but the values for patients were still within normal limits. PSQI score was higher in MS patients compared to controls.
CONCLUSION
Our findings suggest that dimethylfumarate, an oral DMT with a favourable benefit-risk profile, does not strongly alter sleep patterns in MS patients with low to mild disability and with no history of sleep disorders. Actigraphy is a simple diagnostic tool, able to support an objective measure of sleep parameters. The simplicity of application may allow considering its use for a screening of sleep disorders in MS patients.
Identifiants
pubmed: 35570517
pii: CNSNDDT-EPUB-123521
doi: 10.2174/1871527321666220513121138
doi:
Substances chimiques
Dimethyl Fumarate
FO2303MNI2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1102-1108Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.